SG11202109333SA - Delivery of biomolecules to pbmcs to modify an immune response - Google Patents

Delivery of biomolecules to pbmcs to modify an immune response

Info

Publication number
SG11202109333SA
SG11202109333SA SG11202109333SA SG11202109333SA SG11202109333SA SG 11202109333S A SG11202109333S A SG 11202109333SA SG 11202109333S A SG11202109333S A SG 11202109333SA SG 11202109333S A SG11202109333S A SG 11202109333SA SG 11202109333S A SG11202109333S A SG 11202109333SA
Authority
SG
Singapore
Prior art keywords
pbmcs
biomolecules
modify
delivery
immune response
Prior art date
Application number
SG11202109333SA
Inventor
Armon R Sharei
Howard Bernstein
Scott Loughhead
Matthew Booty
Katarina Blagovic
Kelan Hlavaty
Defne Yarar
Emrah Ilker Ozay
Carolyne Kelly Smith
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of SG11202109333SA publication Critical patent/SG11202109333SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
SG11202109333SA 2019-02-28 2020-02-27 Delivery of biomolecules to pbmcs to modify an immune response SG11202109333SA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962812225P 2019-02-28 2019-02-28
EP19161964 2019-03-11
US201962841089P 2019-04-30 2019-04-30
US201962886799P 2019-08-14 2019-08-14
US201962933304P 2019-11-08 2019-11-08
US201962948732P 2019-12-16 2019-12-16
PCT/US2020/020194 WO2020176789A1 (en) 2019-02-28 2020-02-27 Delivery of biomolecules to pbmcs to modify an immune response

Publications (1)

Publication Number Publication Date
SG11202109333SA true SG11202109333SA (en) 2021-09-29

Family

ID=72238527

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109333SA SG11202109333SA (en) 2019-02-28 2020-02-27 Delivery of biomolecules to pbmcs to modify an immune response

Country Status (17)

Country Link
US (1) US11692168B2 (en)
EP (1) EP3931309A4 (en)
JP (1) JP2022522351A (en)
KR (1) KR20210134353A (en)
CN (1) CN114127267A (en)
AU (1) AU2020228648A1 (en)
BR (1) BR112021016903A2 (en)
CA (1) CA3131701A1 (en)
CL (1) CL2021002258A1 (en)
CO (1) CO2021012581A2 (en)
CR (1) CR20210493A (en)
IL (1) IL285809A (en)
MX (1) MX2021010320A (en)
PE (1) PE20220379A1 (en)
SG (1) SG11202109333SA (en)
TW (1) TW202045717A (en)
WO (1) WO2020176789A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CA3131701A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
WO2020210162A1 (en) 2019-04-08 2020-10-15 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
BR112021022789A2 (en) 2019-05-14 2022-04-19 Cedars Sinai Medical Center Methods, systems and devices for selecting patients for tl1a
CR20220576A (en) * 2020-05-11 2022-12-07 Hoffmann La Roche Combination therapy with modified pbmcs and an immunoconjugate
CN116406283A (en) * 2020-09-02 2023-07-07 Sqz生物技术公司 Methods for stimulating HLA-unknown immune responses to proteins using nucleated cells
WO2022147443A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Methods for treating cancers with activating antigen carriers
CA3203709A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations of activating antigen carriers
WO2022147026A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company METHODS FOR TREATING CANCERS WITH MODIFIED PBMCs
CA3203706A1 (en) 2020-12-29 2022-07-07 Howard Bernstein Formulations for cryopreservation of pbmcs
WO2023003907A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502621C3 (en) 1975-01-23 1978-09-14 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Measurement of elastic and dielectric properties of the membrane of living cells
US4376634A (en) 1980-05-30 1983-03-15 Mallinckrodt, Inc. Assay kit having syringe, dilution device and reagents within sealed container
FR2569477B1 (en) 1984-08-24 1987-01-02 Descartes Universite Rene APPARATUS AND METHOD FOR DETERMINING THE DEFORMABILITY OF RED BLOOD CELLS
JP2720161B2 (en) 1988-02-01 1998-02-25 株式会社アドバンス Cell deformability measuring device
JP2685544B2 (en) 1988-11-11 1997-12-03 株式会社日立製作所 Blood filter, blood test method, and blood test apparatus
JP2532707B2 (en) 1990-03-08 1996-09-11 佑二 菊池 Blood circuit, blood measuring apparatus and blood measuring method using the same
AU2002252073A1 (en) 2001-02-22 2002-09-12 The Scepens Eye Research Institute, Inc. Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
CN1604795B (en) 2001-08-17 2010-05-26 科勒制药股份公司 Combination motif immune stimulatory oligonucleotides with improved activity
WO2003020039A1 (en) 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
US7501278B2 (en) 2002-06-05 2009-03-10 Panasonic Corporation Extracellular potential measuring device and method for fabricating the same
US20060134067A1 (en) 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
JP2007528838A (en) 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター Synthetic proteins as tumor-specific vaccines
US8147867B2 (en) 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
JP4116057B2 (en) 2004-06-17 2008-07-09 研 中田 Biomechanical stimulus loading device
CN100591761C (en) 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
US20060134772A1 (en) 2004-11-18 2006-06-22 The Regents Of The University Of California System for locating cells and for cellular analysis
US7704743B2 (en) 2005-03-30 2010-04-27 Georgia Tech Research Corporation Electrosonic cell manipulation device and method of use thereof
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US8293524B2 (en) 2006-03-31 2012-10-23 Fluxion Biosciences Inc. Methods and apparatus for the manipulation of particle suspensions and testing thereof
US20070249038A1 (en) 2006-04-21 2007-10-25 Andrea Adamo Microfluidic device for single cell targeted operations
EP2054499A2 (en) 2006-08-17 2009-05-06 Massachusetts Institute of Technology Method and apparatus for microfluidic injection
US20080241844A1 (en) 2007-02-06 2008-10-02 Network Biosystems, Inc. Devices and Methods for the Performance of Miniaturized In Vitro Assays
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
US20100249621A1 (en) 2007-11-28 2010-09-30 Konica Minolta Opto, Inc. Blood fluidity measurement apparatus and blood fluidity measurement method
US20090280518A1 (en) 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
JP5137129B2 (en) 2008-07-23 2013-02-06 国立大学法人山口大学 Measuring device for mechanical properties of blood cells
EP2321405A4 (en) 2008-08-08 2012-09-12 Agency Science Tech & Res Microfluidic continuous flow device
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US9364831B2 (en) 2009-08-08 2016-06-14 The Regents Of The University Of California Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting
CN102596208B (en) 2009-10-27 2017-06-20 爱瑞泰克药物公司 For the composition of inducing specific immunity tolerance
CN102791616B (en) 2009-12-23 2015-07-29 西托维拉公司 For the system and method for particulate filter
US20120064505A1 (en) 2010-03-22 2012-03-15 Massachusetts Institute Of Technology Measurement of material properties and related methods and compositions
HUE055070T2 (en) 2010-11-25 2021-10-28 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
KR102058568B1 (en) 2011-10-17 2020-01-22 메사추세츠 인스티튜트 오브 테크놀로지 Intracellular delivery
CA2876139A1 (en) 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
EP2981607B1 (en) 2013-04-03 2020-08-19 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AR095882A1 (en) 2013-04-22 2015-11-18 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
SG11201601927SA (en) 2013-08-16 2016-04-28 Massachusetts Inst Technology Selective delivery of material to cells
KR20230098928A (en) * 2014-10-31 2023-07-04 메사추세츠 인스티튜트 오브 테크놀로지 Delivery of biomolecules to immune cells
CA2964138C (en) 2014-11-14 2023-11-14 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
CN107250373A (en) 2015-01-12 2017-10-13 麻省理工学院 The gene editing realized is delivered by microfluid
WO2017008063A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
PL3344747T3 (en) 2015-09-04 2023-06-19 Sqz Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP3397263B1 (en) 2015-12-30 2023-09-20 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
WO2017123663A1 (en) 2016-01-12 2017-07-20 Sqz Biotechnologies Company Intracellular delivery of complexes
RU2021113207A (en) 2016-05-03 2021-09-08 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ INTRACELLULAR DELIVERY OF BIOMOLECULES FOR TOLERANCE INDUCTION
KR102430856B1 (en) 2016-05-03 2022-08-08 에스큐지 바이오테크놀로지스 컴퍼니 Intracellular delivery of biomolecules that induce tolerance
WO2018106849A1 (en) * 2016-12-07 2018-06-14 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
CN111683964A (en) 2017-12-05 2020-09-18 Sqz生物技术公司 Intracellular delivery of biomolecules to modulate antibody production
WO2019126212A1 (en) 2017-12-20 2019-06-27 Sqz Biotechnologies Company System for delivery of a payload into a cell
TW202003025A (en) * 2018-03-12 2020-01-16 美商Ｓｑｚ生物科技公司 Methods for treating HPV-associated diseases
US20210113628A1 (en) 2018-03-12 2021-04-22 Sqz Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
EP3765068A2 (en) 2018-03-12 2021-01-20 SQZ Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
CA3115245A1 (en) 2018-10-04 2020-04-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
US20220105166A1 (en) 2019-01-25 2022-04-07 Sqz Biotechnologies Company Anucleate cell-derived vaccines
CA3131701A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
WO2020210162A1 (en) 2019-04-08 2020-10-15 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell

Also Published As

Publication number Publication date
EP3931309A1 (en) 2022-01-05
US11692168B2 (en) 2023-07-04
MX2021010320A (en) 2021-11-12
US20200318066A1 (en) 2020-10-08
CR20210493A (en) 2022-01-17
KR20210134353A (en) 2021-11-09
CN114127267A (en) 2022-03-01
CL2021002258A1 (en) 2022-06-17
TW202045717A (en) 2020-12-16
EP3931309A4 (en) 2022-12-21
CA3131701A1 (en) 2020-09-03
BR112021016903A2 (en) 2021-11-03
WO2020176789A1 (en) 2020-09-03
IL285809A (en) 2021-10-31
PE20220379A1 (en) 2022-03-18
CO2021012581A2 (en) 2022-01-17
AU2020228648A1 (en) 2021-10-14
JP2022522351A (en) 2022-04-18

Similar Documents

Publication Publication Date Title
IL285809A (en) Delivery of biomolecules to pbmcs to modify an immune response
IL277188A (en) Intracellular delivery of biomolecules to modify immune response
IL268881A (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
IL252005A0 (en) Delivery of biomolecules to immune cells
IL261188A (en) Antibodies to tigit
IL259342B (en) Modulators of chemokine receptors
IL275657A (en) C-kit antibodies
IL279356A (en) Il-11 antibodies
IL279894A (en) Antibodies binding to ilt4
GB201809700D0 (en) IL-11 antibodies
IL273393A (en) Novel anti-cd3epsilon antibodies
IL268731A (en) New uses of anti-sirpg antibodies
IL262244B1 (en) Interferon beta antibodies and uses thereof
HK1256033A1 (en) Use of peptides to stimulate the immune system
EP3288587A4 (en) Modulation of immune response using btla agonist antibodies
IL269394A (en) Antibodies binding to steap-1
IL275079A (en) Daric interleukin receptors
HK1258961A1 (en) Direct affinity measurement of human igg1 binding multimeric antigens
IL281085A (en) Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
SG11202010862VA (en) Compositions for inducing an immune response
ZA202002044B (en) Monoclonal antibody to il-5rα
EP3787643A4 (en) Induction of anti-tumoral immune microenvironments
EP3439697A4 (en) Hydrogel for engineered immune response to d-chirality peptides
ZA202100026B (en) Complex for enhancing immune response
IL272015A (en) Antibodies to MADCAM